FDA’s Prefix Solution On Biologic Names Draws Fire
Executive Summary
Agency’s nomenclature decisions on Teva’s tbo-filgrastim, Genentech’s ado-trastuzumab emtansine have only added to confusion among products, representatives from the American Society of Health-System Pharmacists and World Health Organization said.